Kornimate/medical-research-clean huggingface dataset:
3d imaging of neonatal faces

Conditions: Nose Deformities, Acquired

Summary: facial scans of newborns will be performed before and after implementation of respiratory support devices such as nasal cpap. 3d scanned images will be processed by fisher \& paykel healthcare limited. images will be analyzed for changes or distortion in nasal structure.

any newborns admitted to the neonatal intensive care unit at sharp mary birch hospital for women and newborns between 24-42 weeks cga with parental informed consent are eligible. 3d scanned image will be obtained prior to implementation of nasal support devices and after nasal support devices. fisher \& paykel healthcare limited will analyze the 3d images and observations will be made for changes in nasal structure or distortion.

Eligibility criteria:
inclusion criteria: * infants between 24 and 42 weeks corrected gestational age (inclusive) born at sharp mary birch nicu, * signed informed consent form exclusion criteria: * nasally intubated infants * infants with craniofacial abnormalities

Keywords: 3-dimensional continuous positive airway pressure nasal changes
is routine dissection of central lymph node necessary for papillary thyroid carcinoma, t1-2 n0?

Conditions: Papillary Thyroid Carcinoma

Summary: study assigned into three groups, group i was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups operated by total thyroidectomy and central neck dissection. recurrence free survival (rfs) was the main issue of the study and calculated as the time from date of surgery to date of relapse or the most recent follow-up contact that patient was known as relapse-free, study exclusively studied the outcome and advantage of central neck dissection

informed consent taken, study was a prospective cohort study, with controlled group a retrospectively. patients ablated by total thyroidectomy only who failed to achieve ablation with the first dose of iodine 131i may be dynamically risk stratified as high-risk category and managed aggressively. n0 patients will benefit and ablated by total thyroidectomy and prophylactic central neck dissection, pcnd decreases the residual, increase the rfs and patients without residual do not need adjuvant rai therapy except in high risk group. histological grading, size of the primary tumour, the extension of ptc, the extent of surgery were found to be a strong predicting factor for recurrence-free survival locoregional recurrence cases always found more in male patients aged more than 45 years old. size of the primary tumour and the extent of surgery was a significant factor for rfs,

Eligibility criteria:
inclusion criteria: * age ≥20 years, histopathology proved ptc, with no lymph nodes detected (n0) exclusion criteria: * younger age ≤20 years. prior thyroidectomy, previous radiation exposure, postoperative radioactive iodine therapy, histopathology report of any type of malignancy other than ptc or patients did not complete their postoperative follow-up period. ptc with n1 or n2

Keywords: papillary carcinoma recurrence of ptc radio-iodine therapy for ptc
data acquisition study in inadequately balanced patients with type 2 diabetes mellitus

Conditions: Type2 Diabetes

Summary: the aim of this study is to collect continuous glucose monitoring (cgm) data, coupled with physical activity and everyday day life data. the purpose of this data collection is to help diabetologists to make recommendations to optimize type 2 diabetic patient management.


Eligibility criteria:
inclusion criteria: * type 2 diabetic patient (t2d) with hba1c ≥ 8% in the month prior to inclusion * patient is treated with oral anti-diabetics and / or analogous combined with basal insulin therapy (1 injection of slow-acting insulin in the evening) * age ≥ 35 years * diabetes diagnosis done over 1 year ago * patient accepting for 2 periods of 14 days spaced at most 3 days to wear a freestyle glucose meter, a bracelet for measuring physical activity and to log daily life events in a dedicated smartphone application * patient is able to use a smartphone * patient is affiliated to the french health insurance system exclusion criteria: * patient has type 1 diabetes, diabetes secondary to pancreatic pathology, endocrinopathy or iatrogenic diabetes * patient is treated with a rapid-acting insulin * patient has had a severe hypoglycaemia in the year preceding inclusion * patent has a severe renal insufficiency (defined by a glomerular filtration rate below 30 ml/min) * patient has had a myocardial infarction or other life-threatening medical condition in the last 6 months * patient has cognitive disorders or evolutionary psychiatric pathology * pregnant woman or woman likely to be pregnant, breastfeeding woman * patient plans to travel outside europe during the study * patient is participating to another clinical study
implant radiation therapy using radioactive iodine in treating patients with localized prostate cancer

Conditions: Prostate Cancer

Summary: rationale: implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. purpose: this clinical trial is studying the side effects and how well implant radiation therapy using radioactive iodine works in treating patients with localized prostate cancer.

objectives: * to determine the efficacy of permanent brachytherapy with iodine i 125 seeds in patients with localized prostate cancer. * to determine the safety of this therapy in these patients. outline: this is a multicenter study. patients undergo permanent brachytherapy seed implantation comprised of iodine i 125 into the prostate. some patients may receive combination treatment (e.g., external beam radiation therapy (ebrt) or hormone therapy in addition to brachytherapy). quality of life and the international prostate symptom score (ipss) is assessed and compared.

Eligibility criteria:
disease characteristics: * clinically and histologically confirmed localized prostate cancer patient characteristics: * not specified prior concurrent therapy: * no prior or concurrent surgery * no prior or concurrent radiotherapy * prior chemotherapy, hormonal therapy, and biologic therapy allowed

Keywords: recurrent prostate cancer stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer
evaluation of a protocol of pupil dilation before laser-assisted cataract surgery

Conditions: Cataract Surgery

Summary: laser-assisted cataract surgery is an innovative and growing procedure to improve the safety and results of modern cataract surgery. however, this technique faces to some obstacles: economics in the one hand due to the cost and time spent for the laser procedure before the conventional surgery, and technical in the other hand, especially due to some loss of pupil dilation during the surgery, which is highly important to ensure a perfect procedure. the present study aims at assessing a pharmacological protocol to maintain an accurate pupil dilation all along the surgery in order to improve the whole procedure.

femtosecond laser-assisted cataract surgery (flacs) is a major surgical development that would allow systematization of surgery and even improved safety of the procedure. the development of this new surgical technique must now face certain obstacles, in particular (i) financial considering the extra cost generated by the use of the laser and (ii) technique due to the need to re-learn certain gestures and certain variations related to the laser procedure and more specifically the instability of the pupillary mydriasis (dilatation) during the actual surgery. the use of a systematic preoperative pharmacological mydriasis protocol should allow maximum intraoperative mydriasis to be maintained, allowing satisfactory surgery throughout the procedure. several drugs or medical devices are now indicated in cataract surgery, but their effectiveness has not been specifically evaluated for the laser technique. this study could thus make it possible to validate or not a protocol of mydriasis that could make consensus in the future for the practice of flacs.

Eligibility criteria:
inclusion criteria : * patient with unilateral or bilateral cataract requiring a cataract surgery * patient scheduled for laser-assisted cataract surgery exclusion criteria : * limitation due to laser procedure (little orbits, corneal scares, lack of pharmacological mydriasis at the inclusion visit) * subject with general medication influencing iris state and/or pupil dilation (alpha-agonist, psychotropic drugs) * subject unable to give informed consent * minors
a study of the effectiveness of wafermine alone and in combination with opioids in subjects undergoing bunionectomy

Conditions: Acute Pain

Summary: to evaluate the safety and effectiveness of wafermine administered with and without an opioid medication for acute pain following bunionectomy surgery.

this is a phase 2, randomised, double-blind, double-dummy, placebo-controlled evaluation of the analgesic efficacy and safety of waferminetm alone and in combination with low-dose oxycodone in adult subjects who experience post-operative pain after undergoing primary unilateral bunionectomy. the study will randomise sufficient subjects to have 72 completed subjects at 1 site. study subjects will receive multiple doses of study medication over a 14 hour period and will be asked to complete pain and relief assessments as well as tolerability questionnaires over a 24 hour period.

Eligibility criteria:
inclusion criteria: * scheduled for a bunionectomy (with no additional procedures). * healthy, ambulatory subjects able to understand and willing to comply with study procedures, study restrictions and requirements. * body mass index (bmi) ≥19 to ≤33 kg/m2. * females: not pregnant, not lactating, and not planning to become pregnant during the study. * females: be abstinent, surgically sterile, at least two years post-menopausal; or medically acceptable contraception. * able to read and understand english. * able to swallow oral capsules whole. exclusion criteria: * allergy, intolerance, or contraindication to ketamine, oxycodone, morphine, ibuprofen or surgical medications. * clinically significant medical condition. * history of illicit drug use or alcohol abuse and not in full remission. * positive test for human immunodeficiency virus (hiv), hepatitis b virus (hbv), or hepatitis c virus (hcv) at the screening visit. * clinically significant 12 lead ecg abnormalities at screening. * smokers who are unwilling to abstain during the inpatient stay.

Keywords: bunion bunionectomy
seizures detection in real life setting

Conditions: Epilepsy; Seizure; Focal Epilepsy

Summary: epilepsy is a disabling neurological disease that affects tens of millions of people worldwide. despite therapeutic advances, about a third of these patients suffer from treatment-resistant forms of epilepsy and still experience regular seizures.all seizures can last and lead to status epilepticus, which is a major neurological emergency. epilepsy can also be accompanied with cognitive or psychiatric comorbidities. reliable seizures count is an essential indicator for estimating the care quality and for optimizing treatment. several studies have highlighted the difficulty for patients to keep a reliable seizure diary due for example to memory loss or perception alterations during crisis. whatever the reasons, it has been observed that at least 50% of seizures are on average missed by patients. seizure detection has been widely developed in recent decades and are generally based on physiological signs monitoring associated with biomarkers search and coupled with detection algorithms. multimodal approaches, i.e. combining several sensors at the same time, are considered the most promising. mobile or wearable non invasive devices, allowing an objective seizures documentation in daily life activities, appear to be of major interest for patients and care givers, in detecting and anticipating seizures occurence. this single-arm exploratory, multicenter study aims at assessing whether the use of such a non-invasive, wearable device can be useful in a real life setting in detecting seizures occurence through multimodal analysis of various parameters (heart rate, respiratory and accelerometry).


Eligibility criteria:
inclusion criteria: * patients aged 7 years old or more * patients with drug-resistant focal epilepsy * patients with high frequency seizures according to investigator's judgement * patients that can be followed 4 weeks after inclusion * informed consent form signed. exclusion criteria: * generalised tonic-clonic seizures * frequent psychogenic non-epileptic seizures * pregnant or breastfeeding patients * patients displaying sensor contraindications
impact of the contamination mode on the clinical evolution during pseudomonas aeruginosa ventilator acquired pneumonia (pyo gen)

Conditions: Pseudomonas Aeruginosa; Ventilation Acquired Pneumonia

Summary: pseudomonas aeruginosa is the main pathogen of nosocomial respiratory infections. its increasing resistance to antibiotics requires the development of new strategies for prevention and control, demanding a better understanding of the modes of transmission and evolutionary dynamics of this bacteria. in patients under invasive mechanical ventilation, the main mode of contamination by pseudomonas remains debated, with 3 modes of contamination (endogenous, crossed transmission between patients, or environmental origin) of varying importance, mainly depending on the endemic situation of the place of study. the emergence of new genotyping technologies (diversilab) can now facilitate studies of molecular epidemiology. thanks to the multidisciplinary collaboration and innovative techniques, the investigators wish to study the impact of the mode of contamination on the outcome of icu patients, intubated and ventilated for more than 72 hours.

the presence of environmental reservoirs can cause infections and multidrug-resistant p. aeruginosa colonization with p. aeruginosa is itself a prognostic factor, but the impact of the route of infection on the evolution of the history and future of the infectious patient is not established. a second factor that may influence the evolution infectious is the degree of genetic heterogeneity of the bacterial population. multiple exposure pathways could also influence the genetic diversity.

Eligibility criteria:
inclusion criteria: * patients\> 18 years * hospitalized in the intensive care unit * with more than 72 hours of mechanical ventilation * presenting a positive bacteriological sample p. aeruginosa. exclusion criteria: * minors. * pregnant or lactating women. * patients under guardianship, under judiciary placement, or hospitalized without their consent. * patients not affiliated to a social security scheme. * long-term corticosteroid therapy (\> 2mg/kg or\> 1 month before the onset of established infection suspected) * ongoing chemotherapy, aids, transplant patient under immunosuppressive drugs. * bedridden patient or therapeutic decision at icu arrival

Keywords: pseudomonas aeruginosa ventilated acquired pneumonia transmission modes
endoscopic conversion of sleeve gastrectomy to single anastomosis sleeve-ileal bypass (sasi) for gastroesophageal reflux (gerd), primary and secondary non-responder.

Conditions: Metabolic Syndrome; Severe Obesity; Reflux, Gastroesophageal; Bariatric Surgery

Summary: the aim of this study is to determine the feasibility and effectiveness of endoscopic anastomosis of sleeve gastrectomy to ileum with a lumen apposing metal stent (lams) after a failed sleeve gastrectomy.

the current standard of care for patients who experience insufficient weight loss, weight re-gain or type ii diabetes relapse after a sleeve gastrectomy is a revisional laparoscopic sleeve gastrectomy. however, such revisional procedure is commonly associated with high mortality and morbidity due to protein malnutrition. a noval bariatric procedure, single anastomosis sleeve ileal (sasi) bypass has emerged recently. in this study, we are utilizing an incisionless novel endoscopic technique to efficiently replicate the anatomical features and physiological effects of sasi.

Eligibility criteria:
inclusion criteria: subject must meet all the inclusion criteria to participate in this study and list each criterion. 1. age: 21-65 years 2. patients going for lsg at participating hospitals. 3. able to provide informed consent individuals below age 21 would not be recruited as this is a study in the adult population. individuals above age 65 are excluded to minimize the procedure risk. exclusion criteria: 1. patients who were breast feeding or pregnant 2. severe psychiatric illness 3. eating disorder 4. active neoplastic disease 5. end-stage renal disease 6. patients with bleeding diathesis 7. patients with pacemakers or implantable cardiac defibrillators 8. significant cardiovascular disease (e.g., acute myocardial infarction, congestive cardiac failure, ischemic heart disease, atrial fibrillation, sick sinus syndrome, supraventricular tachycardia) 9. any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other or family members) 10. treatment with anti-platelet agents that could not be temporarily discontinued

Keywords: sasi severe obesity bariatric surgery
study to evaluate the safety and efficacy of stribild versus atripla in human immunodeficiency virus, type 1 (hiv-1) infected, antiretroviral treatment-naive adults

Conditions: HIV; HIV Infections

Summary: to evaluate the safety and efficacy of stribild®, a single tablet regimen (str) containing fixed doses of elvitegravir (evg)/cobicistat (cobi \[gs-9350\])/emtricitabine (ftc)/tenofovir disoproxil fumarate (tdf) versus efavirenz (efv)/ftc/tdf (atripla®) in hiv-1 infected, antiretroviral treatment-naive adults. stribild offers an alternative str for patients who are not candidates for non-nucleoside reverse transcriptor-based strs.


Eligibility criteria:
inclusion criteria: * ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures * plasma hiv-1 rna levels ≥ 5,000 copies/ml * no prior use of any approved or investigational antiretroviral drug for any length of time * screening genotype report must show sensitivity to ftc, tdf, and efv * normal electrocardiogram (ecg) * adequate renal function (estimated glomerular filtration rate ≥ 70 ml/min according to the cockcroft gault formula) * hepatic transaminases (aspartate aminotransferase (ast) and alanine aminotransferase (alt)) ≤ 5 x the upper limit of the normal range (uln) * total bilirubin ≤ 1.5 mg/dl, or normal direct bilirubin * adequate hematologic function * serum amylase ≤ 5 x uln * males and females of childbearing potential must agree to utilize highly effective contraception methods from screening throughout the duration of study treatment and for 12 weeks following the last dose of study drug * age ≥ 18 years * life expectancy ≥ 1 year exclusion criteria: * a new acquired immunodeficiency syndrome (aids)-defining condition diagnosed within the 30 days prior to screening * receiving drug treatment for hepatitis c, or anticipated to receive treatment for hepatitis c * subjects experiencing decompensated cirrhosis * females who are breastfeeding * positive serum pregnancy test (female of childbearing potential) * implanted defibrillator or pacemaker * current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance * history of malignancy within the past 5 years or ongoing malignancy other than cutaneous kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma * active, serious infections (other than hiv-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline * medications contraindicated for use with evg, cobi, ftc, efv, or tdf; or subjects with any known allergies to the excipients of stribild or atripla tablets * participation in any other clinical trial without prior approval * any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements

Keywords: treatment naive hiv 1 infected
kinesiotaping in knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: kinesiotape is one of the treatment choices for the patients with knee osteoarthritis. unlike the brace, it seems to be an important advantage in kinesiotape application in that it permits the movement of the joint. however, kinesiotape is conditionally recommended for knee osteoarthritis in the 2019 american college of rheumatology treatment recommendations due to limiting the quality of evidence, using various application methods, and the lack of blindness concerning its use is not possible. the aim of the study is to determine the effects of kinesiotaping on pain, physical performance, knee range of motion, and postural stability in knee osteoarthritis.

non-pharmacological treatments are recommended as first-line management in knee osteoarthritis. kinesiotape was regarded as a supplementary intervention for patients with knee osteoarthritis. although the results are conflicting, regarding knee osteoarthritis, recently published studies indicate beneficial effects of kinesiotape on knee-related health status, pain, quadriceps muscle strength, and range of motion. on the other hand, the measurements were performed immediately following taping or within a short-term period. the inconsistency of the study data still indicates that the efficacy of kinesiotape in knee osteoarthritis should be evaluated in randomized controlled trials. therefore a study that investigates both short and long-term follow-up results are warranted. this study aimed to determine the immediate and long-term effects of the single and repetitive application of kinesiotape on pain, knee joint range of motion, postural stability, and physical performance in participants with knee osteoarthritis. the results of this study will support evidence-based reports based on the effectiveness of kinesiotape in knee osteoarthritis and recommendations for future studies.

Eligibility criteria:
inclusion criteria: * pain for a minimum of 3 months * pain intensity within the last week minimum of 3 according to the visual analogue scale (vas) at the symptomatic knee * grade 2-3 knee oa according to the kellgren and lawrence scale * ability to perform the tests exclusion criteria: * fragile, very sensitive skin, or lesions in the area * inflammatory arthritis * inability to perform functional tests * pregnancy * use of drugs associated with a psychiatric disorder * previous joint replacement surgery for knee/hip joints * diagnosis with balance disorder * disorders that may cause loss of muscle strength in the lower extremities * previous experience with the kinesiotaping method

Keywords: knee osteoarthritis kinesiotape pain